Join us for an exclusive expert-led webinar featuring Yu-Shin Hsu from Beacon ADC and Callum Angus from Hanson Wade Intelligence as they dissect the rapidly evolving world of antibody-drug conjugate payloads. This dynamic session dives deep into the mechanisms, trends, and safety challenges shaping next-generation therapeutics. From tubulin and topoisomerase inhibitors to promising new alternatives, discover what’s driving innovation – and what it means for the future of ADC development.

Register Now

Key Insights:

  • Payload Mechanisms Decoded: Explore the science behind key payload classes including tubulin and topoisomerase inhibitors, alongside emerging novel options.
  • Data-Driven Trends: Analyze 10+ years of clinical and preclinical development trends to uncover where the field is headed.
  • Safety Under the Microscope: Get a focused review of TOPO1 payload toxicity, including top-line safety data and first-in-human adverse event profiles.
  • Expert Perspectives: Gain strategic insights from two industry leaders with a pulse on current ADC innovation and challenges.

Why Attend?

  • Stay Ahead of the Curve: Understand the evolving landscape of ADC payloads and what’s next in therapeutic innovation.
  • Enhance Strategic Decision-Making: Use real-world data and expert analysis to guide your R&D and clinical strategies.
  • Prioritize Patient Safety: Learn how emerging safety considerations are shaping the development of future ADCs.
  • Engage with Industry Experts: Hear directly from Yu-Shin Hsu and Callum Angus as they share exclusive insights and trend analyses you won’t find anywhere else.

Webinar Leaders

Speaker

Callum Angus
Senior Market Analyst
Hanson Wade Intelligence

 

Speaker

Yu-Shin Hsu
ADC Lead Researcher
Beacon

 

Chair Person

Eleni Taoula
Senior Account Manager
Beacon

 

What is Beacon ADC?

Beacon ADC is a manually curated database solution that includes clinical trial and drug records for preclinical, active, approved and discontinued:

  • ADC (Antibody Drug Conjugates)
  • Immunotoxins
  • SMDCs (Small Molecule Drug Conjugates)
  • Radioimmunoconjugates
  • Ligand Conjugated Nanoparticles
  • Liposomal Drug Conjugate and other comparable modalities

Find out more

Who are Hanson Wade Intelligence?

Outsource your competitive intelligence to Hanson Wade Intelligence and have our analysts support your market landscaping and competitive benchmarking.

Hanson Wade Intelligence are modality experts with multi-project experience in preclinical and clinical evaluation of ADCs, Cell and Gene Therapy, RNA, Protein Degraders and much more. With strong primary and secondary research skills, Hanson Wade Intelligence is ideally positioned to be your CI partner.

Find out more

logo